Prognostic value and expression of p21(wafl/cip I) protein in prostate cancer

Prostate

Volumn 39, Issue 1, 1999, Pages 8-15

  Aaltomaa, S ^a   Lipponen, P ^b   Eskelinen, M ^a   Ala Opas, M ^a   Kosma, V M ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

P21(waf1 cip1); Prognosis; Prostate neoplasm

Indexed keywords

CYCLIN A; CYCLIN D; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DNA REPLICATION; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MITOSIS INHIBITION; MULTIVARIATE ANALYSIS; PH; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 0033560075     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990401)39:1<8::AID-PROS2>3.0.CO;2-N     Document Type: Article

References (48)

1. Isaacs JT. Molecular markers for prostate cancer metastasis. Am J Pathol 1997;150:1511-1521.
2. Byrne RL, Horne CH, Robinson MC, Autzen P, Apakama I, Bishop RI, Neal DE, Hamdy FC. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 1997;79:190-195.
3. Vesalainen SLB, Lipponen PK, Talja MT, Alhava EM, Syrjanen KJ. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma. Int J Cancer 1994;58:303-308.
4. Lipponen P, Vesaleinen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate 1997;32:9-15.
5. Vesalainen S, Lipponen P, Talja M, Syrjänen K. Mitotic activity and prognosis in prostatic adenocarcinoma. Prostate 1995;26:80-86.
6. Vesalainen S, Nordling S, Lipponen P, Talja M, Syrjänen K. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage. Gleason score, S-phase fraction and DNA ploidy. Br J Cancer 1994;70:309-314.
7. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-3753.
8. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84:883-887.
9. Umbas R, Isaacs WB, Bringuier PP, Xue Y, Depryne FM, Schalken JA. Relation between aberrant alfa-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 1997;74:374-377.
10. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-480.
11. Cher ML, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995; 26:87-93.
12. Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB. Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 1994;24:46-53.
13. Harper JW, Adami GR, Wei N, Keyomarski K, Elledge SJ. The p21-Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
14. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-578.
15. Kawasaki T, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/waf1/cip1 and/or p53 gene alterations. Int J Cancer 1996;68:501-505.
16. Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 waf1/cip1 and p16cdkn4) in human prostate cancers. J Urol 1997;158:636-641.
17. Shaw P, Bovey R, Tardy S, Schli R, Jordat B, Costa J. Induction of apoptosis by wild-type p53 in human colon-derived cell line. Proc Natl Acad Sci USA 1992;89:4495-4499.
18. El-Deiry WS, Tokino T, Velculescu VE, Levy FB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75: 817-825.
19. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
20. International Union Against Cancer (UICC). TNM classification of malignant tumors. Geneva: UICC; 1978.
21. Gleason DF. Histological grading and clinical staging of prostate carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea & Febiger; 1977. p 171.
22. Vesalainen S, Lipponen P, Talja M, Syrjänen K. Histological grade, perineural infiltration, tumour infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30:1797-1803.
23. Wyllie AH. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metastasis Rev 1992;11:95-103.
24. Brechot C. Oncogenic activation of cyclin A. Curr Opin Genet Dev 1993;3:11-18.
25. Kato JY. Control of G1 progression by D-type cyclins: key event for cell proliferation. Leukemia 1997;11(suppl 3):347-351.
26. Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjänen K. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997;32:410-415.
27. Gillet CE, Smith P, Gregory WM, Richards MA, Millis RR, Peters G, Barnes DM. Cyclin D1 and prognosis in breast cancer. Int J Cancer 1996;69:92-99.
28. Doglioni C, Pelosio P, Laurino L, Macri E, Meggiolaro E, Favretti F, Barbareschi M. p21/waf1/cip1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 1996;179:248-253.
29. Sasaki K, Sato T, Kurose A, Ikeda E. Immunohistochemical detection of p21(waf1/cip1/sdi1) and p53 proteins in formalin-fixed, paraffin-embedded tissue sections of colorectal carcinoma. Hum Pathol 1996;27:912-916.
30. Dergham ST, Dugan MC, Joshi US, Chen YC, Du W, Smith DW, Arlauskas P, Crissman JD, Vaitkevicus VK, Sarkar FH. The clinical significance of p21(waf1/cip1) and p53 expression in pancreatic cancer. Cancer 1997;80:372-381.
31. Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, Takeda T, Shin E, Takatsuka Y, Kikkawa N, Monden T, Monden M. p21 (waf1/cip1) and p53 protein expression in breast cancer. Am J Clin Pathol 1997;107:684-691,
32. Lipponen P, Aaltomaa S, Eskelinen M, Ala-Opas M, Kosma V-M. Expression of p21(waf1/cip1) protein in transitional cell bladder tumors and its prognostic value. Eur Urol 1998;34:237-243.
33. Chen YQ, Cipriano SC, Arenkiel JM, Miller FR. Tumor suppression by p21 WAF1. Cancer Res 1995;55:4536-4539.
34. El Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Durrell M, Hill DE, Hearly E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B. Topological control of p21(waf1/cip1) expression in normal and neoplastic tissues. Cancer Res 1995;55: 2910-2919.
35. Fredersdorf S, Milne AW, Hall PA, Lu X. Characterisation of a panel of novel anti-p21(waf1/cip21) monoclonal antibodies and immunochemical analysis of p21(waf1/cip1) expression in normal human tissues. Am J Pathol 1996;148:825-835.
36. Trotter MJ, Tang L, Tron VA. Overexpression of the cyclin-dependent kinase inhibitor p21(waf1/cip1) in human cutaneous melanoma. J Cutan Pathol 1997;24:265-271.
37. Nadal A, Jares P, Cazorla M, Fernandez PL, Sanjuan X, Hermandez LL, Pinyol M, Aldea M, Mallofre C, Muntane J, Traserra J, Campo E, Cardesa A. p21(waf1/cip1) expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol 1997;183:156-163.
38. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994;8:1750-1758.
39. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. P53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147:884-888.
40. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pieterpol JA, Bunell M, Hall DE, Wang YS, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B. WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-1174.
41. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-3395.
42. Lipponen P, Aaltomaa S. Apoptosis in transitional cell bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994;173:333-339.
43. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasamitsu T, Nakagawa K, Kikui M, Ohno A, Fukuota M, Kawase I. P21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997;3:1831-1835.
44. Erber R, Klein W, Andl T, Enders C, Born A, Conradt C, Bartek J, Bosch FX. Aberrant p21(waf1/cip1) protein accumulation in head and neck cancer. Int J Cancer 1997;74:383-389.
45. Lin D, Fiscella M, O'Connor PM, Jackman J, Chen M, Luo LL, Sala A, Travali S, Appella E, Mercer WE. Constitutive expression of B-myc can bypass p53-induced waf1/cip1-mediated G1 arrest. Proc Natl Acad Sci USA 1994;91:10079-10083.
46. Palazzo JP, Mercer WE, Kovatich AJ, McHugh M. Immunohistochemical localization of p21(waf1/cip1) in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 1997;27:60-66.
47. Yasu W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, Shimamoto F, Tahara E. Expression of cyclin-dependent kinase inhibitor p21(waf1/cip1) in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996;180:122-128.
48. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor p induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995;92:5545-5549.